Silexion Therapeutics Corp (SLXN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,440 | 6,018 | 9,269 | 3,491 | 6,186 |
| Other current assets | 96 | 49 | 47 | 63 | 58 |
| TOTAL | $4,065 | $6,637 | $11,055 | $5,237 | $7,722 |
| Non-Current Assets | |||||
| PPE Net | 23 | 25 | 26 | 30 | 32 |
| Other Non-Current Assets | 514 | 553 | 533 | 530 | 554 |
| TOTAL | $537 | $578 | $559 | $560 | $586 |
| Total Assets | $4,602 | $7,215 | $11,614 | $5,797 | $8,308 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,465 | 787 | 946 | 692 | 722 |
| Accrued Expenses | 850 | 910 | 945 | 659 | 893 |
| Other current liabilities | 560 | 879 | 721 | 628 | 625 |
| TOTAL | $4,060 | $2,758 | $2,786 | $2,150 | $2,395 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | 1,568 | 1,540 | 3,190 | 2,993 |
| Other Non-Current Liabilities | 251 | 286 | 311 | 337 | 334 |
| TOTAL | $251 | $1,854 | $1,851 | $3,527 | $3,327 |
| Total Liabilities | $4,311 | $4,612 | $4,637 | $5,677 | $5,722 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 4,190 | 3,331 | 3,127 | 732 | 580 |
| Common Shares | 46 | 42 | 42 | 8 | 8 |
| Retained earnings | -57,899 | -55,166 | -50,754 | -47,492 | -44,989 |
| TOTAL | $291 | $2,603 | $6,977 | $120 | $2,586 |
| Total Liabilities And Equity | $4,602 | $7,215 | $11,614 | $5,797 | $8,308 |